Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3
15 sept. 2021 17h55 HE
|
Allarity Therapeutics A/S
Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press...
Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3
14 sept. 2021 17h06 HE
|
Allarity Therapeutics A/S
Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription ...
MINUTES OF EXTRAORDINARY GENERAL MEETING 2021
31 août 2021 15h19 HE
|
Allarity Therapeutics A/S
31 August 2021 ALLARITY THERAPEUTICS A/S On 31 August 2021 at 13:00 (CEST), an extraordinary general meeting of shareholders (the "General Meeting") of Allarity Therapeutics A/S, company...
Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021
26 août 2021 02h32 HE
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (August 26, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces that an accelerated extraordinary and final exercise period for warrants...
Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq
23 août 2021 02h45 HE
|
Allarity Therapeutics A/S
Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth quarter, 2021A previously-announced U.S. $20 million investment by 3i Fund supports Company’s transition to the...
Allarity Therapeutics Publishes Interim Report for the Period January – June 2021
23 août 2021 01h00 HE
|
Allarity Therapeutics A/S
Press ReleaseHørsholm, Denmark (August 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – June 2021. The...
New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report
19 août 2021 15h45 HE
|
Allarity Therapeutics A/S
Press ReleaseHørsholm, Denmark (August 19, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a new publication date for the Company’s Q2 2021 Interim Report, which is now...
Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021
18 août 2021 02h26 HE
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to convene an Extraordinary General Meeting on August 31,...
NOTICE OF EXTRAORDINARY GENERAL MEETING
16 août 2021 17h18 HE
|
Allarity Therapeutics A/S
16 August 2021 ALLARITY THERAPEUTICS A/S31 AUGUST 2021 AT 13:00 (CET) The Board of Directors hereby convenes an Extraordinary General Meeting of Allarity Therapeutics A/S, company registration...
Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus
05 août 2021 07h00 HE
|
Allarity Therapeutics A/S
Current positive results with 3 variants, including alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant) and gamma variant P.1 (“Brazilian” variant), follows...